ClinicalTrials.gg
RecruitingNCT06215716Updated Nov 6, 2026

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

A Phase 3 interventional study of Efruxifermin and Placebo in NASH With Fibrosis and MASH With Fibrosis, sponsored by Akero Therapeutics, Inc. Recruiting at 361 sites in 18 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Akero Therapeutics, Inc (part of Novo Nordisk A/S) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Nov 6, 2026Site recruiting status changed7 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,650
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3).

The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.

Read the detailed description

This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin (EFX) in subjects with non-cirrhotic nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3 (F2 or F3).

Approximately 1,650 subjects will be enrolled into 2 cohorts.

Cohort 1 will enroll approximately 750 subjects with biopsy-confirmed NASH/MASH and fibrosis stage F2 or F3. Subjects in Cohort 1 will undergo evaluation of histologic efficacy endpoints at Week 52.

Cohort 2 will enroll approximately 900 subjects with biopsy-confirmed fibrosis stage F3. Subjects in Cohort 2 may enroll regardless of NAFLD Activity Score (NAS). Subjects in Cohort 2 will undergo liver biopsy assessment at Week 96.

Eligible subjects will be randomized in a 1:1:1 ratio to receive:

  • EFX 28 mg administered subcutaneously once weekly
  • EFX 50 mg administered subcutaneously once weekly
  • Placebo administered subcutaneously once weekly

Subjects will participate in:

  • a screening period of up to 12 weeks,
  • a 52-week primary histology endpoint treatment period (Cohort 1),
  • a 96-week secondary histology endpoint period (Cohort 2),
  • long-term treatment and clinical outcomes follow-up for up to approximately -240 weeks total treatment duration, and
  • a follow-up visit approximately 30 days after the last dose of study drug.

The study will evaluate the effects of EFX compared with placebo on histologic improvement in NASH/MASH, fibrosis regression, noninvasive markers of liver fibrosis, biochemistry markers of lipidic and glycemic metabolism, liver-related clinical outcomes, and long-term safety.

Clinical outcomes assessments include evaluation of liver-related events and all-cause mortality. Key secondary and long-term outcome assessments include evaluation of fibrosis progression, liver stiffness by FibroScan, and Enhanced Liver Fibrosis (ELF) score at prespecified time points including Weeks 96 and 240.

Subjects who discontinue study drug may continue study assessments according to the protocol schedule to support long-term efficacy and safety evaluations.

02

Conditions studied

  • NASH With Fibrosis
  • MASH With Fibrosis
03

In context

Lead sponsor

Akero Therapeutics, Inc is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

First submitted before Akero Therapeutics, Inc became part of Novo Nordisk A/S.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and non-pregnant, non-lactating females between 18 - 80 years of age inclusive, based on the date of the screening visit.
  • Previous history or presence of 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes.
  • Cohort 1: -proven NASH/MASH. Must have had a liver biopsy obtained ≤ 180 days prior to screening with fibrosis stage 2 or 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components:

    • Steatosis (scored 0 to 3),
    • Ballooning degeneration (scored 0 to 2), and
    • Lobular inflammation (scored 0 to 3).
  • Cohort 2: Biopsy-proven fibrosis stage 3. Must have had a liver biopsy obtained ≤ 180 days prior to screening. Subjects with NAS \<4 may be enrolled and are not required to meet 1 point in each of the components of NAS.

Exclusion criteria

Exclusion Criteria:

  • Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results.
  • Presence of cirrhosis on liver (fibrosis stage 4).
  • Type 1 or uncontrolled Type 2 diabetes.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,650 participants (estimated)

Study arms

  • Experimental
    EFX 28 mg

    Drug: Efruxifermin

  • Experimental
    EFX 50 mg

    Drug: Efruxifermin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Administered by subcutaneous injection

  • DrugPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Cohort 1 Only: Resolution of NASH/MASH and a ≥ 1 stage improvement in fibrosis

    Based on NAS (scored by 0-3 for steatosis, 0-3 for inflammation, and 0-2 for ballooning) and NASH CRN fibrosis score (scored by a fibrosis score of 0-4, where 0 = no fibrosis, 1 = perisinusoidal or periportal fibrosis, 2 = perisinusoidal and portal/periportal fibrosis, 3 = bridging fibrosis, 4 = cirrhosis)

    Time frame: 52 Weeks

  2. Event-free survival

    Based on time from randomization to the first clinical event including evidence of disease progression, liver decompensation events, liver transplantation or eligibility for liver transplantation, and all-cause mortality.

    Time frame: 240 Weeks

Secondary outcomes

  1. Cohort 1 Only: Resolution of NASH/MASH and no worsening of fibrosis

    Based on NAS (scored by 0-3 for steatosis, 0-3 for inflammation, and 0-2 for ballooning) and NASH CRN fibrosis score (scored by a fibrosis score of 0-4, where 0 = no fibrosis, 1 = perisinusoidal or periportal fibrosis, 2 = perisinusoidal and portal/periportal fibrosis, 3 = bridging fibrosis, 4 = cirrhosis)

    Time frame: 52 Weeks

  2. Cohort 1 Only: ≥ 1 stage improvement in fibrosis and no worsening of steatohepatitis

    Based on NAS (scored by 0-3 for steatosis, 0-3 for inflammation, and 0-2 for ballooning) and NASH CRN fibrosis score (scored by a fibrosis score of 0-4, where 0 = no fibrosis, 1 = perisinusoidal or periportal fibrosis, 2 = perisinusoidal and portal/periportal fibrosis, 3 = bridging fibrosis, 4 = cirrhosis)

    Time frame: 52 Weeks

  3. Change from baseline of non-invasive markers of liver fibrosis: Fibroscan

    Liver stiffness assessed by transient elastography (FibroScan)

    Time frame: 96 Weeks, 240 Weeks

  4. Change from baseline in non-invasive markers of liver fibrosis: ELF score

    The ELF score measures the severity of liver fibrosis and estimates the risk of disease progression to cirrhosis or liver-related events, with higher scores indicating higher liver fibrosis level and higher risk of disease progression.

    Time frame: 96 Weeks, 240 Weeks

  5. Progression to Cirrhosis F4 Based on NASH CRN Fibrosis Score

    NASH CRN fibrosis score (scored by a fibrosis score of 0-4, where 0 = no fibrosis, 1 = perisinusoidal or periportal fibrosis, 2 = perisinusoidal and portal/periportal fibrosis, 3 = bridging fibrosis, 4 = cirrhosis)

    Time frame: 96 Weeks and 240 Weeks

  6. Change from baseline of non-invasive markers of liver fibrosis: ELF score

    The ELF score measures the severity of liver fibrosis and estimates the risk of disease progression to cirrhosis or liver-related events, with higher scores indicating higher liver fibrosis level and higher risk of disease progression.

    Time frame: 52 Weeks

  7. Change from baseline of non-invasive markers of liver fibrosis: ELF score components (TIMP-1, HA, PIIINP, Pro-C3)

    Tissue inhibitor of metalloproteinase-1 \[TIMP-1\], hyaluronic acid \[HA\], amino terminal pro-peptide of type 3 procollagen \[PIIINP\]), and propeptide of type 3 procollagen (Pro-C3)

    Time frame: 52 Weeks

  8. Change from baseline of non-invasive markers of liver fibrosis: Fibroscan

    Liver stiffness assessed by transient elastography (FibroScan)

    Time frame: 52 Weeks

  9. Change from baseline in non-invasive markers of liver fibrosis: ELF score components: TIMP-1, HA, PIIINP, Pro-C3

    The ELF score measures the severity of liver fibrosis and estimates the risk of disease progression to cirrhosis or liver-related events, with higher scores indicating higher liver fibrosis level and higher risk of disease progression.

    Time frame: Week 240

  10. Change from baseline of markers of liver injury: ALT, AST, GGT

    ALT (U/L), AST (U/L), GGT (U/L)

    Time frame: 52 Weeks, 240 Weeks

  11. Change from baseline of markers of liver injury: Uric Acid

    Uric acid (mg/dL)

    Time frame: 52 Weeks, 240 Weeks

  12. Change from baseline of lipoproteins: Total cholesterol, TG, Non-HDL-C, HDL-C, and LDL-C

    Total cholesterol (mg/dL), TG (mg/dL), Non-HDL-C (mg/dL), HDL-C (mg/dL), and LDL-C (mg/dL)

    Time frame: 52 Weeks, 240 Weeks

  13. Change from baseline of markers of insulin sensitivity and glycemic control: HbA1c

    HbA1c (%)

    Time frame: 52 Weeks, 240 Weeks

  14. Change from baseline of markers of insulin sensitivity and glycemic control: Adiponectin

    Adiponectin (mg/L)

    Time frame: 52 Weeks, 240 Weeks

  15. Change from baseline of body weight (kg)

    Time frame: 52 Weeks, 240 Weeks

  16. To assess the safety and tolerability of EFX through the reporting of extent of exposure (weeks)

    Time frame: 52 Weeks, 240 Weeks

  17. To assess the safety and tolerability of EFX through the reporting of adverse events (severity of events)

    Time frame: 52 Weeks, 240 Weeks

  18. To assess the safety and tolerability of EFX through the reporting of adverse events (frequency of events)

    Time frame: 52 Weeks, 240 Weeks

  19. To assess the safety and tolerability of EFX through the reporting of abnormal clinical laboratory tests, ECGs, ultrasounds, vital sign assessments (number of patients)

    Time frame: 52 Weeks, 240 Weeks

  20. To assess the immunogenicity of EFX through the reporting of antidrug antibodies (number of patients)

    Time frame: 52 Weeks, 240 Weeks

07

Study locations

299 of 361 sites recruiting
  • Akero Clinical Study Site
    Birmingham, Alabama 35209, United States
    Recruiting
    • Akero Site 0129 · Contact
  • Akero Clinical Study Site
    Dothan, Alabama 36301, United States
    Recruiting
    • Akero Site 0233 · Contact
  • Akero Clinical Study Site
    Chandler, Arizona 85224, United States
    Recruiting
    • Akero Site 9106 · Contact
  • Akero Clinical Study Site
    Flagstaff, Arizona 86001, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Peoria, Arizona 85381, United States
    Recruiting
    • Akero Site 9104 · Contact
  • Akero Clinical Study Site
    Tucson, Arizona 85712, United States
    Recruiting
    • Akero Site 9210 · Contact
  • Akero Clinical Study Site
    Tucson, Arizona 85712, United States
    Recruiting
    • Akero Site 9144 · Contact
  • Akero Clinical Study Site
    Tucson, Arizona 85713, United States
    Recruiting
    • Akero Site 0234 · Contact
  • Akero Clinical Study Site
    Tucson, Arizona 85715, United States
    Recruiting
    • Akero Site 0209 · Contact
  • Akero Clinical Study Site
    Conway, Arkansas 72032, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Jonesboro, Arkansas 72401, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Little Rock, Arkansas 72205, United States
    Recruiting
    • Akero Site 0106 · Contact
  • Akero Clinical Study Site
    North Little Rock, Arkansas 72117, United States
    Recruiting
    • Akero Site 9214 · Contact
  • Akero Clinical Study Site
    Chula Vista, California 91910, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Coronado, California 92118, United States
    Recruiting
    • Akero Site 0132 · Contact
  • Akero Clinical Study Site
    Escondido, California 92025, United States
    Recruiting
    • Akero Site 0266 · Contact
  • Akero Clinical Study Site
    Folsom, California 95630, United States
    Recruiting
    • Akero Site 0263 · Contact
  • Akero Clinical Study Site
    Inglewood, California 90301, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    La Mesa, California 91942, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Lancaster, California 93534, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Lancaster, California 93534, United States
    Recruiting
    • Akero Site 0285 · Contact
  • Akero Clinical Study Site
    Long Beach, California 90815, United States
    Recruiting
    • Akero Site 0188 · Contact
  • Akero Clinical Study Site
    Los Angeles, California 90036, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Los Angeles, California 90048, United States
    Recruiting
    • Akero Site 0236 · Contact
  • Akero Clinical Study Site
    Los Angeles, California 90057, United States
    Recruiting
    • Akero Site 0168 · Contact
  • Akero Clinical Study Site
    Newport Beach, California 92663, United States
    Recruiting
    • Akero Site 0206 · Contact
  • Akero Clinical Study Site
    Orange, California 92868, United States
    Recruiting
    • Akero Site 0261 · Contact
  • Akero Clinical Study Site
    Palm Springs, California 92262, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Pasadena, California 91105, United States
    Recruiting
    • Akero Site 9250 · Contact
  • Akero Clinical Study Site
    Redwood City, California 94063, United States
    Recruiting
    • Akero Site 0191 · Contact
  • Akero Clinical Study Site
    Sacramento, California 95817, United States
    Recruiting
    • Akero Site 0274 · Contact
  • Akero Clinical Study Site
    San Diego, California 92120, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    San Diego, California 92123, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    San Diego, California 92161, United States
    Recruiting
    • Akero Site 0199 · Contact
  • Akero Clinical Study Site
    San Francisco, California 94115, United States
    Recruiting
    • Akero Site 0147 · Contact
  • Akero Clinical Study Site
    San Francisco, California 94117, United States
    Recruiting
    • Akero Site 0269 · Contact
  • Akero Clinical Study Site
    Santa Maria, California 93458, United States
    Recruiting
    • Akero Site 0205 · Contact
  • Akero Clinical Study Site
    Aurora, Colorado 80045, United States
    Recruiting
    • Akero Site 0217 · Contact
  • Akero Clinical Study Site
    Colorado Springs, Colorado 80907, United States
    Recruiting
    • Akero Site 0260 · Contact
  • Akero Clinical Study Site
    Englewood, Colorado 80113, United States
    Recruiting
    • Akero Site 9243 · Contact
  • Akero Clinical Study Site
    New Haven, Connecticut 06520, United States
    Recruiting
    • Akero Site 0213 · Contact
  • Akero Clinical Study Site
    Washington D.C., District of Columbia 20007, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Washington D.C., District of Columbia 20422, United States
    Recruiting
    • Akero Site 0262 · Contact
  • Akero Clinical Study Site
    Bradenton, Florida 34208, United States
    Recruiting
    • Akero Site 0153 · Contact
  • Akero Clinical Study Site
    Brandon, Florida 33511, United States
    Recruiting
    • Akero Site 0222 · Contact
  • Akero Clinical Study Site
    Doral, Florida 33126, United States
    Recruiting
    • Akero Site 0267 · Contact
  • Akero Clinical Study Site
    Fort Myers, Florida 33912, United States
    Recruiting
    • Akero Site 9134 · Contact
  • Akero Clinical Study Site
    Gainesville, Florida 32610, United States
    Recruiting
    • Akero Site 0114 · Contact
  • Akero Clinical Study Site
    Hialeah Gardens, Florida 33016, United States
    Recruiting
    • Akero Site 9242 · Contact
  • Akero Clinical Study Site
    Inverness, Florida 34452, United States
    Recruiting
    • Akero Site 9135 · Contact
  • Akero Clinical Study Site
    Jacksonville, Florida 32256, United States
    Recruiting
    • Akero Site 0118 · Contact
  • Akero Clinical Study Site
    Lady Lake, Florida 32159, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Lakewood Rch, Florida 34211, United States
    Recruiting
    • Akero Site 9203 · Contact
  • Akero Clinical Study Site
    Largo, Florida 33777, United States
    Recruiting
    • Akero Site 9248 · Contact
  • Akero Clinical Study Site
    Lehigh Acres, Florida 33936, United States
    Recruiting
    • Akero Site 0271 · Contact
  • Akero Clinical Study Site
    Maitland, Florida 32751, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Margate, Florida 33063, United States
    Recruiting
    • Akero Site 0248 · Contact
  • Akero Clinical Study Site
    Miami, Florida 33136, United States
    Recruiting
    • Akero Site 0137 · Contact
  • Akero Clinical Study Site
    Miami, Florida 33175, United States
    Recruiting
    • Akero Site 0252 · Contact
  • Akero Clinical Study Site
    Miami Gardens, Florida 33014, United States
    Recruiting
    • Akero Site 0243 · Contact
  • Akero Clinical Study Site
    Miami Lakes, Florida 33016, United States
    Recruiting
    • Akero Site 9138 · Contact
  • Akero Clinical Study Site
    Naples, Florida 34102, United States
    Recruiting
    • Akero Site 0138 · Contact
  • Akero Clinical Study Site
    New Port Richey, Florida 34653, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Ocala, Florida 34471, United States
    Recruiting
    • Akero Site 9127 · Contact
  • Akero Clinical Study Site
    Orlando, Florida 32807, United States
    Recruiting
    • Akero Site 0250 · Contact
  • Akero Clinical Study Site
    Pembroke Pines, Florida 33027, United States
    Recruiting
    • Akero Site 0239 · Contact
  • Akero Clinical Study Site
    Port Orange, Florida 32127, United States
    Recruiting
    • Akero Site 9105 · Contact
  • Akero Clinical Study Site
    Riverview, Florida 33578, United States
    Recruiting
    • Akero Site 0295 · Contact
  • Akero Clinical Study Site
    Sarasota, Florida 34240, United States
    Recruiting
    • Akero Site 9218 · Contact
  • Akero Clinical Study Site
    Temple Terrace, Florida 33617, United States
    Recruiting
    • Akero Site 0242 · Contact
  • Akero Clinical Study Site
    Venice, Florida 34285, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Viera, Florida 32940, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    West Palm Beach, Florida 33401, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Weston, Florida 33331, United States
    Recruiting
    • Akero Site 0270 · Contact
  • Akero Clinical Study Site
    Winter Park, Florida 32789, United States
    Recruiting
    • Akero Site 0157 · Contact
  • Akero Clinical Study Site
    Winter Park, Florida 32792, United States
    Recruiting
    • Akero Site 0187 · Contact
  • Akero Clinical Study Site
    Zephyrhills, Florida 33542, United States
    Recruiting
    • Akero Site 0235 · Contact
  • Akero Clinical Study Site
    Atlanta, Georgia 30309, United States
    Recruiting
    • Akero Site 0230 · Contact
  • Akero Clinical Study Site
    Columbus, Georgia 31904, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Gainesville, Georgia 30501, United States
    Recruiting
    • Akero Site 0183 · Contact
  • Akero Clinical Study Site
    Marietta, Georgia 30060, United States
    Recruiting
    • Akero Site 9111 · Contact
  • Akero Clinical Study Site
    Chicago, Illinois 60637, United States
    Recruiting
    • Akero Site 9245 · Contact
  • Akero Clinical Study Site
    Hammond, Indiana 46324, United States
    Recruiting
    • Akero Site 0254 · Contact
  • Akero Clinical Study Site
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Akero Site 0290 · Contact
  • Akero Clinical Study Site
    South Bend, Indiana 46635, United States
    Recruiting
    • Akero Site 9235 · Contact
  • Akero Clinical Study Site
    West Des Moines, Iowa 50265, United States
    Recruiting
    • Akero Site 0146 · Contact
  • Akero Clinical Study Site
    Topeka, Kansas 66606, United States
    Recruiting
    • Akero Site 9136 · Contact
  • Akero Clinical Study Site
    Wichita, Kansas 67205, United States
    Completed

    Not enrolling at this site — choose another above.

  • Akero Clinical Study Site
    Louisville, Kentucky 40202, United States
    Recruiting
    • Akero Site 0203 · Contact
  • Akero Clinical Study Site
    Bastrop, Louisiana 71220, United States
    Recruiting
    • Akero Site 9220 · Contact
  • Akero Clinical Study Site
    Covington, Louisiana 70433, United States
    Recruiting
    • Akero Site 0195 · Contact
  • Akero Clinical Study Site
    Houma, Louisiana 70363, United States
    Recruiting
    • Akero Site 0112 · Contact
  • Akero Clinical Study Site
    Marrero, Louisiana 70072, United States
    Recruiting
    • Akero Site 9102 · Contact
  • Akero Clinical Study Site
    Metairie, Louisiana 70006, United States
    Recruiting
    • Akero Site 0109 · Contact
  • Akero Clinical Study Site
    New Orleans, Louisiana 70112, United States
    Recruiting
    • Akero Site 0196 · Contact
  • Akero Clinical Study Site
    New Orleans, Louisiana 70121, United States
    Recruiting
    • Akero Site 0176 · Contact
  • Akero Clinical Study Site
    Shreveport, Louisiana 71105, United States
    Recruiting
    • Akero Site 9145 · Contact
  • Akero Clinical Study Site
    West Monroe, Louisiana 71291, United States
    Recruiting
    • Akero Site 0283 · Contact
  • Akero Clinical Study Site
    Baltimore, Maryland 21202, United States
    Recruiting
    • Akero Site 0108 · Contact
  • Akero Clinical Study Site
    Glen Burnie, Maryland 21061, United States
    Completed

    Not enrolling at this site — choose another above.

Showing the first 100 of 361 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Feb 2033, 110 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Jan 22, 2024
StartActual
Dec 1, 2023
Primary completionEst.
Feb 2033
CompletionEst.
Feb 2033
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 2 sites removed. 21 sites changed recruiting status (20 now completed, 1 now active, not recruiting)
Show 21 sites
  • Akero Clinical Study Site · Inglewood, United StatesRecruiting→Completed
  • Akero Clinical Study Site · Palm Springs, United StatesRecruiting→Completed
  • Akero Clinical Study Site · San Diego, United StatesRecruiting→Completed
  • Akero Clinical Study Site · Columbus, United StatesRecruiting→Completed
  • Akero Clinical Study Site · Las Vegas, United StatesRecruiting→Completed
  • Akero Clinical Study Site · Dallas, United StatesRecruiting→Completed
  • Akero Clinical Study Site · Lewisville, United StatesRecruiting→Completed
  • Akero Clinical Study Site · San Antonio, United StatesRecruiting→Completed
  • Akero Clinical Study Site · San Marcos, United StatesRecruiting→Completed
  • Akero Clinical Study Site · Waco, United StatesRecruiting→Completed
  • Akero Clinical Study Site · Ogden, United StatesRecruiting→Completed
  • Akero Clinical Study Site · Newport News, United StatesRecruiting→Completed
  • Akero Clinical Study Site · Buenos Aires, ArgentinaRecruiting→Completed
  • Akero Clinical Study Site · Surat, IndiaRecruiting→Completed
  • Akero Clinical Study Site · Vadodara, IndiaRecruiting→Completed
  • Akero Clinical Study Site · Pune, IndiaRecruiting→Completed
  • Akero Clinical Study Site · Petah Tikva, IsraelRecruiting→Completed
  • Akero Clinical Study Site · Nazareth, IsraelRecruiting→Completed
  • Akero Clinical Study Site · Seongnam-si, South KoreaRecruiting→Completed
  • Akero Clinical Study Site · Yenimahalle, Turkey (Türkiye)Recruiting→Completed
  • Akero Clinical Study Site · Gdynia, PolandRecruiting→Active, not recruiting
Show 7 added (4 Mexico, 1 India, 1 Italy, 1 Poland)
  • Akero Clinical Study Site · Secunderabad, India
  • Akero Clinical Study Site · Roma, Italy
  • Akero Clinical Study Site · Warsaw, Poland
  • Akero Clinical Study Site · Acapulco de Juárez, Mexico
  • Akero Clinical Study Site · Mexico City, Mexico
  • Akero Clinical Study Site · Mexico City, Mexico
  • Akero Clinical Study Site · Mexico City, Mexico
Show 2 removed
  • Akero Clinical Study Site · San Antonio, United States
  • Akero Clinical Study Site · San Marcos, United States
across 3 updates, Oct 6, 2026 – Nov 6, 2026
Secondary outcomes
2 time frame changed, 1 added
What changed in the outcomes
  • AddedProgression to Cirrhosis F4 Based on NASH CRN Fibrosis ScoreTime frame: 96 Weeks and 240 Weeks
  • Time frameChange from baseline of non-invasive markers of liver fibrosis: Fibroscan52 Weeks → 96 Weeks, 240 Weeks
  • Time frameChange from baseline of non-invasive markers of liver fibrosis: Fibroscan#296 Weeks, 240 Weeks → 52 Weeks
Oct 6, 2026
Site contacts
Changed at 20 sites. See the sites
Show 20 sites
  • Akero Clinical Study Site · Inglewood, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · Palm Springs, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · San Diego, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · Columbus, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · Las Vegas, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · Dallas, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · Lewisville, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · San Antonio, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · San Marcos, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · Waco, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · Ogden, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · Newport News, United StatesContact removed (no phone or email listed)
  • Akero Clinical Study Site · Buenos Aires, ArgentinaContact removed (no phone or email listed)
  • Akero Clinical Study Site · Surat, IndiaContact removed (no phone or email listed)
  • Akero Clinical Study Site · Vadodara, IndiaContact removed (no phone or email listed)
  • Akero Clinical Study Site · Pune, IndiaContact removed (no phone or email listed)
  • Akero Clinical Study Site · Petah Tikva, IsraelContact removed (no phone or email listed)
  • Akero Clinical Study Site · Nazareth, IsraelContact removed (no phone or email listed)
  • Akero Clinical Study Site · Yenimahalle, Turkey (Türkiye)Contact removed (no phone or email listed)
  • Akero Clinical Study Site · Gdynia, PolandContact removed (no phone or email listed)
across 2 updates, Oct 6, 2026 – Oct 15, 2026
Show all 3 updates
  1. Nov 6, 2026
    2 sites added
    Show 2 added (2 Mexico)
    • Akero Clinical Study Site · Mexico City, Mexico
    • Akero Clinical Study Site · Mexico City, Mexico
    + 1 other change: verification date
  2. Oct 15, 2026
    2 sites added. Akero Clinical Study Site is now Active, not recruiting
    Show 2 added (2 Mexico)
    • Akero Clinical Study Site · Acapulco de Juárez, Mexico
    • Akero Clinical Study Site · Mexico City, Mexico
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Akero Clinical Study Site · Gdynia, PolandContact removed (no phone or email listed)
    + 1 other change: verification date
  3. Oct 6, 2026
    3 sites added, 2 sites removed. 20 sites changed recruiting status (20 now completed)
    Show 20 sites
    • Akero Clinical Study Site · Inglewood, United StatesRecruiting→Completed
    • Akero Clinical Study Site · Palm Springs, United StatesRecruiting→Completed
    • Akero Clinical Study Site · San Diego, United StatesRecruiting→Completed
    • Akero Clinical Study Site · Columbus, United StatesRecruiting→Completed
    • Akero Clinical Study Site · Las Vegas, United StatesRecruiting→Completed
    • Akero Clinical Study Site · Dallas, United StatesRecruiting→Completed
    • Akero Clinical Study Site · Lewisville, United StatesRecruiting→Completed
    • Akero Clinical Study Site · San Antonio, United StatesRecruiting→Completed
    • Akero Clinical Study Site · San Marcos, United StatesRecruiting→Completed
    • Akero Clinical Study Site · Waco, United StatesRecruiting→Completed
    • Akero Clinical Study Site · Ogden, United StatesRecruiting→Completed
    • Akero Clinical Study Site · Newport News, United StatesRecruiting→Completed
    • Akero Clinical Study Site · Buenos Aires, ArgentinaRecruiting→Completed
    • Akero Clinical Study Site · Surat, IndiaRecruiting→Completed
    • Akero Clinical Study Site · Vadodara, IndiaRecruiting→Completed
    • Akero Clinical Study Site · Pune, IndiaRecruiting→Completed
    • Akero Clinical Study Site · Petah Tikva, IsraelRecruiting→Completed
    • Akero Clinical Study Site · Nazareth, IsraelRecruiting→Completed
    • Akero Clinical Study Site · Seongnam-si, South KoreaRecruiting→Completed
    • Akero Clinical Study Site · Yenimahalle, Turkey (Türkiye)Recruiting→Completed
    Show 3 added (1 India, 1 Italy, 1 Poland)
    • Akero Clinical Study Site · Secunderabad, India
    • Akero Clinical Study Site · Roma, Italy
    • Akero Clinical Study Site · Warsaw, Poland
    Show 2 removed
    • Akero Clinical Study Site · San Antonio, United States
    • Akero Clinical Study Site · San Marcos, United States
    Secondary outcomes 2 time frame changed, 1 added
    What changed in the outcomes
    • AddedProgression to Cirrhosis F4 Based on NASH CRN Fibrosis ScoreTime frame: 96 Weeks and 240 Weeks
    • Time frameChange from baseline of non-invasive markers of liver fibrosis: Fibroscan52 Weeks → 96 Weeks, 240 Weeks
    • Time frameChange from baseline of non-invasive markers of liver fibrosis: Fibroscan#296 Weeks, 240 Weeks → 52 Weeks
    Site contacts Changed at 19 sites. See the sites
    Show 19 sites
    • Akero Clinical Study Site · Inglewood, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · Palm Springs, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · San Diego, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · Columbus, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · Las Vegas, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · Dallas, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · Lewisville, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · San Antonio, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · San Marcos, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · Waco, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · Ogden, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · Newport News, United StatesContact removed (no phone or email listed)
    • Akero Clinical Study Site · Buenos Aires, ArgentinaContact removed (no phone or email listed)
    • Akero Clinical Study Site · Surat, IndiaContact removed (no phone or email listed)
    • Akero Clinical Study Site · Vadodara, IndiaContact removed (no phone or email listed)
    • Akero Clinical Study Site · Pune, IndiaContact removed (no phone or email listed)
    • Akero Clinical Study Site · Petah Tikva, IsraelContact removed (no phone or email listed)
    • Akero Clinical Study Site · Nazareth, IsraelContact removed (no phone or email listed)
    • Akero Clinical Study Site · Yenimahalle, Turkey (Türkiye)Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06215716
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
Dec 1, 2023
Primary completion
Feb 2033 (estimated)
Completion
Feb 2033 (estimated)
Last update
Nov 6, 2026

Study contacts

Akero Study Director
Contact
AkeroSynchrony@akerotx.com
650-487-6488

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efruxifermin

Start the discussion